Stefan Verlohren

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8860048/publications.pdf

Version: 2024-02-01

77 papers	5,535 citations	117625 34 h-index	79698 73 g-index
101 all docs	101 docs citations	101 times ranked	4284 citing authors

#	Article	IF	Citations
1	The diagnostic value of angiogenic and antiangiogenic factors in differential diagnosis of preeclampsia. American Journal of Obstetrics and Gynecology, 2022, 226, S1048-S1058.	1.3	34
2	The growing body of evidence for the implementation of the soluble fms-like tyrosine kinase 1/placental growth factor ratio into clinical routine. American Journal of Obstetrics and Gynecology, 2022, 226, 157.	1.3	0
3	Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia. Pregnancy Hypertension, 2022, 27, 42-50.	1.4	55
4	A machine-learningâ€"based algorithm improves prediction of preeclampsia-associated adverse outcomes. American Journal of Obstetrics and Gynecology, 2022, 227, 77.e1-77.e30.	1.3	20
5	sFlt-1/PlGF ratio for prediction of preeclampsia in clinical routine: A pragmatic real-world analysis of healthcare resource utilisation. PLoS ONE, 2022, 17, e0263443.	2.5	9
6	Correlation between placental weight and angiogenic markers sFlt-1 and PlGF in women with preeclampsia and fetal growth restriction. Pregnancy Hypertension, 2022, 28, 149-155.	1.4	1
7	Prognostic significance of prenatal ultrasound in fetal arthrogryposis multiplex congenita. Archives of Gynecology and Obstetrics, 2021, 303, 943-953.	1.7	5
8	Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1 (Soluble fms-Like Tyrosine Kinase) Tj ETQq0 0 0 rgBT /Overlock 10	2.7	81
9	Gestational Age-Specific Reference Ranges for the sFlt-1/PlGF Immunoassay Ratio in Twin Pregnancies. Fetal Diagnosis and Therapy, 2021, 48, 288-296.	1.4	14
10	Maternale Erkrankungen in der Schwangerschaft. , 2021, , 337-609.		0
11	Short Term Prediction of Preeclampsia. Maternal-Fetal Medicine, 2021, 3, 107-115.	0.8	4
12	Preeclampsia: Universal Screening or Universal Prevention for Low and Middle-Income Settings?. Revista Brasileira De Ginecologia E Obstetricia, 2021, 43, 334-338.	0.8	4
13	A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of preâ€eclampsia. International Journal of Gynecology and Obstetrics, 2021, 154, 3-31.	2.3	34
14	Relevance of maternal sodium level for preeclampsia-associated adverse pregnancy outcomes. Pregnancy Hypertension, 2021, 25, 110-115.	1.4	4
15	Cost-utility of a first-trimester screening strategy versus the standard of care for nulliparous women to prevent pre-term pre-eclampsia in Belgium. Pregnancy Hypertension, 2021, 25, 219-224.	1.4	12
16	Differential diagnosis of syndromic craniosynostosis: a case series. Archives of Gynecology and Obstetrics, 2021, , 1.	1.7	1
17	From firstâ€trimester screening to risk stratification of evolving preâ€eclampsia in second and third trimesters of pregnancy: comprehensive approach. Ultrasound in Obstetrics and Gynecology, 2020, 55, 5-12.	1.7	24
18	Statins Reverse Postpartum Cardiovascular Dysfunction in a Rat Model of Preeclampsia. Hypertension, 2020, 75, 202-210.	2.7	27

#	Article	IF	Citations
19	Role of placenta in development of preâ€eclampsia: revisited. Ultrasound in Obstetrics and Gynecology, 2020, 56, 803-808.	1.7	6
20	Kagamiâ€Ogata syndrome: an important differential diagnosis to Beckwithâ€Wiedemann syndrome. Journal of Clinical Ultrasound, 2020, 48, 240-243.	0.8	10
21	Soluble fmsâ€like tyrosine kinaseâ€1 to placental growth factor ratio: ruling out preâ€eclampsia for up to 4 weeks and value of retesting. Ultrasound in Obstetrics and Gynecology, 2019, 53, 367-375.	1.7	86
22	Author's reply re: Preâ€eclampsia is primarily a placental disorder: <scp>FOR</scp>: Preâ€eclampsia is primarily a placental disorder. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 513-514.	2.3	0
23	Update on the Diagnosis and Prognosis of Preeclampsia with the Aid of the sFlt-1/ PlGF Ratio in Singleton Pregnancies. Fetal Diagnosis and Therapy, 2018, 43, 81-89.	1.4	102
24	54. Cardiac small vessel imaging by light sheet microscopy and micro CT â€“ discovering the missing link between preeclampsia and higher risk for further cardiovascular disease. Pregnancy Hypertension, 2018, 13, S63.	1.4	1
25	Soluble B7â€H4 blood serum levels are elevated in women at high risk for preeclampsia in the first trimester, as well as in patients with confirmed preeclampsia. American Journal of Reproductive Immunology, 2018, 80, e12988.	1.2	11
26	Re: Addition of N-terminal pro-B natriuretic peptide to soluble fms-like tyrosine kinase-1/placental growth factor ratio >â€‰38 improves prediction of pre-eclampsia requiring delivery within 1â€‰week: a longitudinal cohort study. E. SabriÃ¡, P. Lequerica-FernÃ¡. Ultrasound in Obstetrics and Gynecology, 2018, 51, 718-718.	1.7	0
27	Diagnosis of preeclampsia and fetal growth restriction with the sFlt-1/PlGF ratio: Diagnostic accuracy of the automated immunoassay KryptorÂ®. Pregnancy Hypertension, 2017, 8, 31-36.	1.4	15
28	Placental expression of sFlt-1 and PlGF in early preeclampsia vs. early IUGR vs. age-matched healthy pregnancies. Hypertension in Pregnancy, 2017, 36, 151-160.	1.1	33
29	Increased placental sFlt-1 but unchanged PlGF expression in late-onset preeclampsia. Hypertension in Pregnancy, 2017, 36, 175-185.	1.1	15
30	Angiogenic Markers and Cardiovascular Indices in the Prediction of Hypertensive Disorders of Pregnancy. Hypertension, 2017, 69, 1192-1197.	2.7	59
31	Re: Screening for pre-eclampsia using sFlt-1/PlGF ratio cut-off of 38 at 30-37 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2017, 49, 665-666.	1.7	1
32	Pre-eclampsia is primarily a placental disorder. BJOG: an International Journal of Obstetrics and Gynaecology, 2017, 124, 1762-1762.	2.3	5
33	Re: Rational and irrational ratios. Ultrasound in Obstetrics and Gynecology, 2017, 49, 157-158.	1.7	3
34	Maternale Erkrankungen in der Schwangerschaft. , 2016, , 347-618.		0
35	Predictive Value of the sFlt-1. Obstetrical and Gynecological Survey, 2016, 71, 273-274.	0.4	4
36	Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio and Time to Delivery in Women With Suspected Preeclampsia. Obstetrics and Gynecology, 2016, 128, 261-269.	2.4	65

#	Article	IF	Citations
37	A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome. Hypertension in Pregnancy, 2016, 35, 295-305.	1.1	42
38	The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. New England Journal of Medicine, 2016, 374, 1785-1786.	27.0	29
39	Natural Killer Cell Reduction and Uteroplacental Vasculopathy. Hypertension, 2016, 68, 964-973.	2.7	14
40	Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. New England Journal of Medicine, 2016, 374, 13-22.	27.0	1,158
41	Implementation of the <scp>sFlt</scp>â€1/<scp>PlGF</scp> ratio for prediction and diagnosis of preâ€eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound in Obstetrics and Gynecology, 2015, 45, 241-246.	1.7	196
42	Characterization of the Soluble Fms-like Tyrosine Kinase-1 to Placental Growth Factor Ratio in Pregnancies Complicated by Fetal Growth Restriction. Obstetric Anesthesia Digest, 2015, 35, 90-91.	0.1	0
43	Acral necrosis and upper brachial plexus palsy after prenatal fetal thrombosis. Case Reports in Perinatal Medicine, 2015, 4, .	0.1	0
44	Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. Prenatal Diagnosis, 2015, 35, 386-393.	2.3	28
45	Maternal serum <scp>sFlt</scp>â€1/<scp>PlGF</scp> ratio in twin pregnancies with and without preâ€eclampsia in comparison with singleton pregnancies. Ultrasound in Obstetrics and Gynecology, 2015, 45, 286-293.	1.7	56
46	Update on the Pathophysiological Implications and Clinical Role of Angiogenic Factors in Pregnancy. Fetal Diagnosis and Therapy, 2015, 37, 81-92.	1.4	59
47	Placental lesions of vascular insufficiency are associated with anti-angiogenic state in women with preeclampsia. Hypertension in Pregnancy, 2014, 33, 427-439.	1.1	38
48	Uterine artery Doppler, birth weight and timing of onset of pre-eclampsia: providing insights into the dual etiology of late-onset pre-eclampsia. Ultrasound in Obstetrics and Gynecology, 2014, 44, 293-298.	1.7	106
49	Re: Longitudinal changes in maternal soluble endoglin and angiopoietinâ€2 in women at risk for preâ€eclampsia. A. Khalil, N. Maiz, R. Garciaâ€Mandujano, M. Elkhouli and K. H. Nicolaides. Ultrasound Obstet Gynecol 2014; 44: 402â€“410. Ultrasound in Obstetrics and Gynecology, 2014, 44, 386-386.	1.7	1
50	Characterization of the Soluble fms-Like Tyrosine Kinase-1 to Placental Growth Factor Ratio in Pregnancies Complicated by Fetal Growth Restriction. Obstetrics and Gynecology, 2014, 124, 265-273.	2.4	86
51	New Gestational Phaseâ€“Specific Cutoff Values for the Use of the Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor Ratio as a Diagnostic Test for Preeclampsia. Hypertension, 2014, 63, 346-352.	2.7	261
52	The importance of repeated measurements of the sFlt-1/PlGF ratio for the prediction of preeclampsia and intrauterine growth restriction. Journal of Perinatal Medicine, 2014, 42, 61-68.	1.4	63
53	SLC41A1is the only magnesium responsive gene significantly overexpressed in placentas of preeclamptic women. Hypertension in Pregnancy, 2013, 32, 378-389.	1.1	24
54	Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertension in Pregnancy, 2013, 32, 189-201.	1.1	130

#	Article	IF	Citations
55	Antiangiogenic factors and maternal hemodynamics during intensive hemodialysis in pregnancy. Hemodialysis International, 2013, 17, 639-643.	0.9	17
56	Automated measurement of sFlt1, PlGF and sFlt1/PlGF ratio in differential diagnosis of hypertensive pregnancy disorders. Hypertension in Pregnancy, 2013, 32, 459-473.	1.1	29
57	Re: Uterine artery Doppler and sFlt-1/PlGF ratio: usefulness in diagnosis of pre-eclampsia. P. I. GÃ³mez-Arriaga, I. Herraiz, E. A. LÃ³pez-JimÃ©nez, E. GÃ³mez-Montes, B. Denk and A. Galindo.Ultrasound Obstet Gynecol2013; 41: 530-537. Ultrasound in Obstetrics and Gynecology, 2013, 41, 489-490.	1.7	1
58	Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clinical Science, 2012, 122, 43-52.	4.3	121
59	Cytochrome P450 Subfamily 2J Polypeptide 2 Expression and Circulating Epoxyeicosatrienoic Metabolites in Preeclampsia. Circulation, 2012, 126, 2990-2999.	1.6	57
60	Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia. Circulation, 2012, 125, 911-919.	1.6	526
61	Circulating Angiogenic Factors and Risk of Adverse Maternal and Perinatal Outcomes in Twin Pregnancies With Suspected Preeclampsia. Hypertension, 2012, 60, 451-458.	2.7	84
62	The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. American Journal of Obstetrics and Gynecology, 2012, 206, 58.e1-58.e8.	1.3	339
63	L13. The routine measurement of the sFlt1/PlGF ratio allows differential diagnosis of hypertensive pregnancy disorders and has prognostic potential in preeclamptic patients. Pregnancy Hypertension, 2011, 1, 245-246.	1.4	6
64	P9. The elecsys assay for PlGF, sFlt1 and their ratio (sFlt1/PlGF) as an aid in differential diagnosis of pregnancy-related hypertensive disorders. Pregnancy Hypertension, 2011, 1, 276-277.	1.4	1
65	Changes in endovascular trophoblast invasion and spiral artery remodelling at term in a transgenic preeclamptic rat model. Placenta, 2010, 31, 320-326.	1.5	36
66	An automated method for the determination of the sFlt-1/PlGF ratio in the assessment of preeclampsia. American Journal of Obstetrics and Gynecology, 2010, 202, 161.e1-161.e11.	1.3	342
67	Inhibition of Trophoblast-Induced Spiral Artery Remodeling Reduces Placental Perfusion in Rat Pregnancy. Hypertension, 2010, 56, 304-310.	2.7	64
68	Effects of Circulating and Local Uteroplacental Angiotensin II in Rat Pregnancy. Hypertension, 2010, 56, 311-318.	2.7	64
69	Prevalence of Agonistic Autoantibodies Against the Angiotensin II Type 1 Receptor and Soluble fms-Like Tyrosine Kinase 1 in a Gestational Ageâ€“Matched Case Study. Hypertension, 2009, 53, 393-398.	2.7	87
70	Immunology in Hypertension, Preeclampsia, and Target-Organ Damage. Hypertension, 2009, 54, 439-443.	2.7	52
71	Hypoxia Induces Dilated Cardiomyopathy in the Chick Embryo: Mechanism, Intervention, and Long-Term Consequences. PLoS ONE, 2009, 4, e5155.	2.5	105
72	Endovascular Trophoblast Invasion, Spiral Artery Remodelling and Uteroplacental Haemodynamics in a Transgenic Rat Model of Pre-eclampsia. Placenta, 2008, 29, 614-623.	1.5	59

#	Article	IF	Citations
73	Trophoblasts Reduce the Vascular Smooth Muscle Cell Proatherogenic Response. Hypertension, 2008, 51, 554-559.	2.7	29
74	Uterine Vascular Function in a Transgenic Preeclampsia Rat Model. Hypertension, 2008, 51, 547-553.	2.7	74
75	Potential Relevance of Î±1-Adrenergic Receptor Autoantibodies in Refractory Hypertension. PLoS ONE, 2008, 3, e3742.	2.5	79
76	Soluble Vascular Endothelial Growth Factor Receptor-1 (sFLT-1) Mediates Downregulation of FLT-1 and Prevents Activated Neutrophils From Women With Preeclampsia From Additional Migration by VEGF. Circulation Research, 2005, 97, 1253-1261.	4.5	38
77	Visceral Periadventitial Adipose Tissue Regulates Arterial Tone of Mesenteric Arteries. Hypertension, 2004, 44, 271-276.	2.7	253